766 research outputs found
A neuroimaging investigation of bipolar disorder and the neurocognitive effects of 5-HT7 antagonists
Bipolar disorder is a psychiatric disorder characterised by pathological mood states, but there is growing recognition of the role of cognitive impairment and dysfunction of emotional processes, which has a profound impact on quality of life. Many people with bipolar disorders exhibit brain volume impairment associated with cognitive dysfunction and an increased risk of dementia. In this thesis, I conducted a systematic review to understand the relationships between mood disorders and the 5-HT7 receptor. The 5-HT7 receptor is related to depression and anxiety, but the relationship between 5-HT7 and mania remains unclear; in addition, sleep and memory were also related to the 5-HT7 receptor. Followed by these findings, in the next two chapters, I examined the effects of 5-HT7 antagonists, using JNJ-18038683, on emotional and cognitive functioning, as well as their neural substrates. I then reported on neuroimaging investigations examining the effects of 5-HT7 antagonists on emotional processing and cognitive function in healthy volunteers to gain insight into their potential mode of action and utility for bipolar disorder. In fMRI analyses, the drug acted on 5-HT7 receptors potentially improving cognitive performance by modulating the function of the Cognitive Control Network in healthy controls. In the above-mentioned chapters, I gained a better understanding of the 5-HT7 antagonist, JNJ-18038683, and the putative promising effects for pharmacological treatments. However, the approach taken has some limitations, including a small sample size, potential participant bias, and a lack of systematic control of medication dose and duration of administration. In addition, in Chapter 5, I explored the brain basis of bipolar disorder and its links to cognitive and emotional dysfunction using a new ‘brain age’ approach. Individuals with bipolar disorder were found to have increased brain age compared to healthy controls. I hope that these findings can be applied to pharmacological treatment for individuals with bipolar disorder, ultimately allowing patients to benefit from the drug in the future
Analytical validation of innovative magneto-inertial outcomes: a controlled environment study.
peer reviewe
Cerebrovascular dysfunction in cerebral small vessel disease
INTRODUCTION:
Cerebral small vessel disease (SVD) is the cause of a quarter of all ischaemic strokes and is postulated to have a role in up to half of all dementias. SVD pathophysiology remains unclear but cerebrovascular dysfunction may be important. If confirmed many licensed medications have mechanisms of action targeting vascular function, potentially enabling new treatments via drug repurposing. Knowledge is limited however, as most studies assessing cerebrovascular dysfunction are small, single centre, single imaging modality studies due to the complexities in measuring cerebrovascular dysfunctions in humans. This thesis describes the development and application of imaging techniques measuring several cerebrovascular dysfunctions to investigate SVD pathophysiology and trial medications that may improve small blood vessel function in SVD.
METHODS:
Participants with minor ischaemic strokes were recruited to a series of studies utilising advanced MRI techniques to measure cerebrovascular dysfunction. Specifically MRI scans measured the ability of different tissues in the brain to change blood flow in response to breathing carbon dioxide (cerebrovascular reactivity; CVR) and the flow and pulsatility through the cerebral arteries, venous sinuses and CSF spaces. A single centre observational study optimised and established feasibility of the techniques and tested associations of cerebrovascular dysfunctions with clinical and imaging phenotypes. Then a randomised pilot clinical trial tested two medications’ (cilostazol and isosorbide mononitrate) ability to improve CVR and pulsatility over a period of eight weeks. The techniques were then expanded to include imaging of blood brain barrier permeability and utilised in multi-centre studies investigating cerebrovascular dysfunction in both sporadic and monogenetic SVDs.
RESULTS:
Imaging protocols were feasible, consistently being completed with usable data in over 85% of participants. After correcting for the effects of age, sex and systolic blood pressure, lower CVR was associated with higher white matter hyperintensity volume, Fazekas score and perivascular space counts. Lower CVR was associated with higher pulsatility of blood flow in the superior sagittal sinus and lower CSF flow stroke volume at the foramen magnum. Cilostazol and isosorbide mononitrate increased CVR in white matter. The CVR, intra-cranial flow and pulsatility techniques, alongside blood brain barrier permeability and microstructural integrity imaging were successfully employed in a multi-centre observational study. A clinical trial assessing the effects of drugs targeting blood pressure variability is nearing completion.
DISCUSSION:
Cerebrovascular dysfunction in SVD has been confirmed and may play a more direct role in disease pathogenesis than previously established risk factors. Advanced imaging measures assessing cerebrovascular dysfunction are feasible in multi-centre studies and trials. Identifying drugs that improve cerebrovascular dysfunction using these techniques may be useful in selecting candidates for definitive clinical trials which require large sample sizes and long follow up periods to show improvement against outcomes of stroke and dementia incidence and cognitive function
Artificial Intelligence for Cognitive Health Assessment: State-of-the-Art, Open Challenges and Future Directions
The subjectivity and inaccuracy of in-clinic Cognitive Health Assessments (CHA) have led many researchers to explore ways to automate the process to make it more objective and to facilitate the needs of the healthcare industry. Artificial Intelligence (AI) and machine learning (ML) have emerged as the most promising approaches to automate the CHA process. In this paper, we explore the background of CHA and delve into the extensive research recently undertaken in this domain to provide a comprehensive survey of the state-of-the-art. In particular, a careful selection of significant works published in the literature is reviewed to elaborate a range of enabling technologies and AI/ML techniques used for CHA, including conventional supervised and unsupervised machine learning, deep learning, reinforcement learning, natural language processing, and image processing techniques. Furthermore, we provide an overview of various means of data acquisition and the benchmark datasets. Finally, we discuss open issues and challenges in using AI and ML for CHA along with some possible solutions. In summary, this paper presents CHA tools, lists various data acquisition methods for CHA, provides technological advancements, presents the usage of AI for CHA, and open issues, challenges in the CHA domain. We hope this first-of-its-kind survey paper will significantly contribute to identifying research gaps in the complex and rapidly evolving interdisciplinary mental health field
Optimisation, evaluation and application of cerebrovascular reactivity measurement using magnetic resonance imaging in patients with cerebral small vessel disease
Small vessel disease (SVD) is a common cause of strokes and dementia. Currently, there are no treatments; therefore, developing and validating early biomarkers of disease progression and treatment response is important for future drug trials. Though SVD pathogenesis is not well understood, findings from previous studies suggest that blood-brain barrier dysfunction and impaired cerebrovascular reactivity (CVR) contribute to the disease. The latter can be measured in vivo using a vasoactive stimulus in parallel with magnetic resonance imaging (MRI) techniques sensitive to blood flow, such as blood oxygen level dependent (BOLD) contrast, and has frequently been assessed in patients with steno-occlusive diseases. However, it is unclear if the technique is reliable when investigating cerebrovascular health in deep structures of the brain where SVD is prevalent. Therefore, this thesis aimed to assess and optimise the reliability of CVR measurements and deepen our understanding of its role in SVD pathogenesis.
A systematic review was performed to provide a detailed overview of CVR MRI methodologies and clinical applications, including SVD, present in the literature, which identified several acquisition and analysis methods, a need for greater standardisation and lack of data on reliability. Specifically in SVD research, there was limited application of CVR MRI in SVD populations, little optimisation and reliability assessment of CVR in deep brain structures relevant to SVD, such as in white and subcortical grey matter. Following those findings, the effects of voxel- and region-based analysis approaches on reliability of CVR estimates were investigated using simulations and test-retest data from healthy volunteers. Voxel-based CVR magnitude estimates in tissues with high noise levels were prone to bias, whereas biases in region-based estimates were independent of noise level, but consistently underestimated CVR magnitude relative to the ground-truth mean. Furthermore, the test-retest study confirmed the repeatability of CVR estimates from a BOLD-CVR experiment with fixed inhaled stimulus, although a systematic, but small, bias was detected due to habituation to the gas challenge. The data from healthy volunteers were further used to conduct a proof-of-concept and investigate the feasibility of extracting cerebral pulsatility from BOLD-CVR data. Small-to-moderate correlations with pulsatility from phase-contrast MRI were found depending on the regions considered. CVR pulsatility was also computed in a small cohort of SVD patients: it was higher than in healthy volunteers, but no associations were found with SVD burden. It was concluded that further optimisation and validation of the technique is needed before being suitable for clinical research. Following the optimisation of the CVR MRI technique, relationships between CVR and SVD neuroimaging features, cognition, stroke severity and outcome were investigated cross-sectionally and longitudinally in a cohort of patients with mild stroke. In the cross-sectional analysis, CVR impairment in normal-appearing and damaged tissues was associated with worse SVD burden and cognition deficit. Furthermore, the longitudinal analysis showed that baseline CVR impairment predicted worsening of white matter hyperintensity and perivascular space volumes after one year.
In conclusion, assessment of CVR in the brain and its deeper structures was successfully conducted in healthy volunteers and patients with SVD using MRI. However, this required appropriate optimisation of processing strategy as the latter can affect accuracy of CVR parameters and inter-study comparability. Importantly, applying the technique in a cohort of SVD patients led to the findings that CVR impairment was related to worse SVD burden and is a potential marker of SVD severity and progression
Analysis of the retina and visual pathway by OCT, OCTA and psychophysical tests in asymptomatic subjects at high genetic risk for the development of Alzheimer's disease
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, leÃda el 15-07-2022La Enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa progresiva que se caracteriza: por una atrofia cortical difusa, declive de las funciones cognitivas, asà como la agregación anormal de proteÃnas como la beta amiloide fibrilar (Aß) y tau hiperfosforilada (p-Tau).El factor de riesgo prevalente es la edad avanzada, tras el cual destaca la herencia genética. Elmayor factor de riesgo genético conocido es ser portador de al menos un alelo 4 del gen de la apoliproteina E (ApoE). Otro de los factores que incrementa el riesgo para desarrollar la EA, es la historia familiar de primer grado. Los signos cerebrales de la EA aparecen décadas antes del inicio clÃnico de la enfermedad. Dado que la relación entre cerebro y retina se establece ya desde la etapa embrionaria, los cambios retinianos detectados con técnicas de diagnóstico oftalmológico en sujetos con alto riesgo genético para el desarrollo de EA posibilitan la identificación de potenciales pacientes de EA en etapas muy tempranas...Alzheimer's disease (AD) is a progressive neurodegenerative disease characterised by: diffuse cortical atrophy, decline in cognitive functions, as well as abnormal aggregation of proteins such as fibrillar amyloid Beta (Aβ) and hyperphosphorylated tau(p-Tau).The prevalent risk factor is older age, after which genetic inheritance is the most important. The major known genetic risk factor is carrying at least one 4 allele of the apoliprotein E (ApoE 4)gene. Another factor that increases the risk of developing AD is a first-degree family history. Brain signs of AD appear decades before clinical onset of the disease. Since the relationship between brain and retina is established as early as the embryonic stage, retinal changes detected with ophthalmological diagnostic techniques in subjects at high genetic risk for developing AD make it possible to identify potential AD patients at very early stages..Fac. de MedicinaTRUEunpu
A clinicopathological investigation of brainstem nuclei in Lewy body dementia
Introduction: Lewy Body Dementias (LBD) - Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD) - are clinical diagnoses based on the one-year rule and varied symptom onset. Previously, degeneration of the locus coeruleus (LC) and dorsal raphe nucleus (DRN) in LBD has been well established. However, the precise relationship between underlying neuropathology and clinical presentation remains to be determined.
Methods: Immunohistochemical and image analysis techniques have been performed to examine neuronal loss and protein pathologies in the noradrenergic and serotonergic systems of 20 PD, 20 PD-MCI, 20 PDD, 20 DLB cases and 20 controls. RNAscope technology was used to decipher the role of cell-surface receptors in LBD pathophysiology. Possible associations between administration of pharmacological agents with LBD pathology and disease duration was also examined.
Results: The hippocampus, thalamus and cingulate cortex - crucial components of the Papez circuit - were most affected by the proteinopathies, particularly deposition that correlated with the onset of some DLB symptomatology and non-motor symptoms. LC noradrenergic neurons were reduced in LBD compared to PD. The 5-HT2A receptor seemed to be more abundant than the α2A-adrenergic receptor (AR) and serotonin transporter (SERT) in the frontal cortex of a PD patient than a PDD or DLB patient.
Conclusion: LBD phenotypes may be differentiated through their limbic involvement in the Papez circuit, where α-syn accumulation may contribute to non-motor symptoms. The behaviour of each protein type may be extremely heterogenous within each region of the noradrenergic and serotonergic systems, such that it correlates with the onset of different symptoms. There may be lower expression of receptors in LBD than PD patients, perhaps due to end-stage disease and more widespread degeneration. Hence, this study may have provided further insights into LBD pathophysiology and possibly assist clinical trials in future therapeutic interventions.Open Acces
- …